The European Commission wants to make health data easier to access by 2025 for patients, medics, regulators and researchers in a bid to improve diagnoses, cut unnecessary costs from duplication of medical tests and boost medicine research.
ReutersWalgreens Boots Alliance and Teva Pharmaceutical Industries Ltd. ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on April 25 during opening statements of the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
BrandShield, together with the Pharmaceutical Security Institute, announced its findings following a disruption program carried out from December 2020 to November 2021 involving the monitoring, detecting and removal of online threats.
Prescription drug watchdog GoodRx compiled a list of the 10 most expensive drugs on the market.
At the start of 2021, 70 companies raised the price of hundreds of prescription drugs by an average of 3.3%.
Drug companies’ political committees have largely donated to Republican presidential campaigns since 1990, but that trend has noticeably reversed come the 2020 election cycle, according to a new report from the Center for Responsive Politics.
Russia approved R-Pharm’s Coronavir treatment for outpatients with mild to moderate Covid-19 infections and the antiviral drug could be rolled out to pharmacies in the country within a week, the company said.
U.S. President Donald Trump signed four executive orders aiming at lowering prices that Americans pay for prescription drugs as he faces an uphill re-election battle and criticism over his handling of the coronavirus pandemic.
A quarter of healthcare organizations’ revenue is tied to value-based payments, according to a survey by the healthcare data analytics and policy company DataGen. Those with 550 or more beds reported the largest portion of risk, with an average of 37.9 percent of revenue tied to VBP.
Aspen Pharmacare said Mylan NV exercised an option to buy the South African drugmaker’s portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million).
